175 related articles for article (PubMed ID: 22911730)
1. Bezafibrate for X-linked adrenoleukodystrophy.
Engelen M; Tran L; Ofman R; Brennecke J; Moser AB; Dijkstra IM; Wanders RJ; Poll-The BT; Kemp S
PLoS One; 2012; 7(7):e41013. PubMed ID: 22911730
[TBL] [Abstract][Full Text] [Related]
2. Enzymatic characterization of ELOVL1, a key enzyme in very long-chain fatty acid synthesis.
Schackmann MJ; Ofman R; Dijkstra IM; Wanders RJ; Kemp S
Biochim Biophys Acta; 2015 Feb; 1851(2):231-7. PubMed ID: 25499606
[TBL] [Abstract][Full Text] [Related]
3. Bezafibrate lowers very long-chain fatty acids in X-linked adrenoleukodystrophy fibroblasts by inhibiting fatty acid elongation.
Engelen M; Schackmann MJ; Ofman R; Sanders RJ; Dijkstra IM; Houten SM; Fourcade S; Pujol A; Poll-The BT; Wanders RJ; Kemp S
J Inherit Metab Dis; 2012 Nov; 35(6):1137-45. PubMed ID: 22447153
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of pharmacological induction of fatty acid beta-oxidation in X-linked adrenoleukodystrophy.
McGuinness MC; Zhang HP; Smith KD
Mol Genet Metab; 2001; 74(1-2):256-63. PubMed ID: 11592822
[TBL] [Abstract][Full Text] [Related]
5. [X-linked adrenoleukodystrophy].
Aubourg P
Ann Endocrinol (Paris); 2007 Dec; 68(6):403-11. PubMed ID: 17532287
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy.
Asheuer M; Bieche I; Laurendeau I; Moser A; Hainque B; Vidaud M; Aubourg P
Hum Mol Genet; 2005 May; 14(10):1293-303. PubMed ID: 15800013
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol-deprivation increases mono-unsaturated very long-chain fatty acids in skin fibroblasts from patients with X-linked adrenoleukodystrophy.
Engelen M; Ofman R; Mooijer PA; Poll-The BT; Wanders RJ; Kemp S
Biochim Biophys Acta; 2008 Mar; 1781(3):105-11. PubMed ID: 18206987
[TBL] [Abstract][Full Text] [Related]
8. Caffeic acid phenethyl ester induces adrenoleukodystrophy (Abcd2) gene in human X-ALD fibroblasts and inhibits the proinflammatory response in Abcd1/2 silenced mouse primary astrocytes.
Singh J; Khan M; Singh I
Biochim Biophys Acta; 2013 Apr; 1831(4):747-58. PubMed ID: 23318275
[TBL] [Abstract][Full Text] [Related]
9. Lipid-induced endoplasmic reticulum stress in X-linked adrenoleukodystrophy.
van de Beek MC; Ofman R; Dijkstra I; Wijburg F; Engelen M; Wanders R; Kemp S
Biochim Biophys Acta Mol Basis Dis; 2017 Sep; 1863(9):2255-2265. PubMed ID: 28666219
[TBL] [Abstract][Full Text] [Related]
10. The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy.
Ofman R; Dijkstra IM; van Roermund CW; Burger N; Turkenburg M; van Cruchten A; van Engen CE; Wanders RJ; Kemp S
EMBO Mol Med; 2010 Mar; 2(3):90-7. PubMed ID: 20166112
[TBL] [Abstract][Full Text] [Related]
11. Cytokine-induced accumulation of very long-chain fatty acids in rat C6 glial cells: implication for X-adrenoleukodystrophy.
Khan M; Pahan K; Singh AK; Singh I
J Neurochem; 1998 Jul; 71(1):78-87. PubMed ID: 9648853
[TBL] [Abstract][Full Text] [Related]
12. Induced pluripotent stem cell models from X-linked adrenoleukodystrophy patients.
Jang J; Kang HC; Kim HS; Kim JY; Huh YJ; Kim DS; Yoo JE; Lee JA; Lim B; Lee J; Yoon TM; Park IH; Hwang DY; Daley GQ; Kim DW
Ann Neurol; 2011 Sep; 70(3):402-9. PubMed ID: 21721033
[TBL] [Abstract][Full Text] [Related]
13. Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy.
Kemp S; Valianpour F; Denis S; Ofman R; Sanders RJ; Mooyer P; Barth PG; Wanders RJ
Mol Genet Metab; 2005 Feb; 84(2):144-51. PubMed ID: 15670720
[TBL] [Abstract][Full Text] [Related]
14. HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes.
Singh J; Khan M; Singh I
J Lipid Res; 2011 Nov; 52(11):2056-69. PubMed ID: 21891797
[TBL] [Abstract][Full Text] [Related]
15. Detection of Characteristic Phosphatidylcholine Containing Very Long Chain Fatty Acids in Cerebrospinal Fluid from Patients with X-Linked Adrenoleukodystrophy.
Fujitani N; Saito M; Akashi T; Morita M; So T; Oka K
Biol Pharm Bull; 2022; 45(11):1725-1727. PubMed ID: 36328509
[TBL] [Abstract][Full Text] [Related]
16. [Adrenoleukodystrophy: molecular pathogenesis and development of therapeutic agents].
Morita M
Yakugaku Zasshi; 2007 Jul; 127(7):1059-64. PubMed ID: 17603264
[TBL] [Abstract][Full Text] [Related]
17. X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects.
Kemp S; Berger J; Aubourg P
Biochim Biophys Acta; 2012 Sep; 1822(9):1465-74. PubMed ID: 22483867
[TBL] [Abstract][Full Text] [Related]
18. Is subclinical adrenal failure in adrenoleukodystrophy/adrenomyeloneuropathy reversible?
Cappa M; Bizzarri C; Giannone G; Aiello C; Di Biase A
J Endocrinol Invest; 2011 Nov; 34(10):753-6. PubMed ID: 21399389
[TBL] [Abstract][Full Text] [Related]
19. Astrocytes and mitochondria from adrenoleukodystrophy protein (ABCD1)-deficient mice reveal that the adrenoleukodystrophy-associated very long-chain fatty acids target several cellular energy-dependent functions.
Kruska N; Schönfeld P; Pujol A; Reiser G
Biochim Biophys Acta; 2015 May; 1852(5):925-36. PubMed ID: 25583114
[TBL] [Abstract][Full Text] [Related]
20. Biochemical aspects of X-linked adrenoleukodystrophy.
Kemp S; Wanders R
Brain Pathol; 2010 Jul; 20(4):831-7. PubMed ID: 20626744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
